NGS液態切片市場:現狀分析與預測(2023年～2028年)

NGS-based liquid biopsy Market: Current Analysis and Forecast (2023-2028)

出版日期: 2023年06月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於全球醫療機構不斷加強癌症意識計劃，NGS液體活檢市場預計將以16.8%的速度穩定增長。

按類型劃分，市場分為套件、設備和服務。2022年，套件行業主導市場。下一代測序（NGS）液體活檢市場的試劑盒部分在促進液體活檢樣本中生物標誌物的準確、高效檢測方面發揮著關鍵作用。此外，套件的成本效益和低可用性是推動該細分市場增長的主要因素之一。

按最終用戶劃分，市場分為診斷實驗室、醫院、診所等。其中，醫院類別將在2022年佔據市場主導地位。這主要是由於癌症病例數量的增加，而住院患者數量的增加是醫院業務增長的主要驅動力。

為了更好地了解NGS液體活檢行業的市場採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區）、亞太地區（中國、日本）、印度以及亞太地區其他地區）以及世界其他地區。2022年，北美地區在全球NGS液體活檢市場中佔據最大市場佔有率，佔有率為42.2%。由於美國和加拿大等新興國家在該地區的存在，NGS液體活檢市場正在不斷增長。此外，由於對癌症診斷（包括NGS液體活檢）的需求不斷增加，癌症發病率持續上升是該地區面臨的一個主要問題。例如，根據 Globocan 2020 報告，2020 年北美報告了 250 萬癌症病例。據報導，其中 699,274 人死亡。

NGS technologies have revolutionized liquid biopsy by enabling the detection and analysis of genetic alterations, such as mutations, copy number variations, and chromosomal rearrangements, with high sensitivity and accuracy. This approach has gained considerable attention in oncology for cancer diagnosis, monitoring treatment response, detecting minimal residual disease, and identifying potential drug resistance mechanisms. The market for NGS-based liquid biopsy is mainly driven by the increasing prevalence of cancer worldwide, the need for personalized medicine approaches, and the growing demand for non-invasive and real-time monitoring of cancer progression. For instance, as per the World Health Organization (WHO), Cancer was one of the leading causes of death worldwide, killing nearly 10 million people in 2020.

The NGS-Based Liquid Biopsy Market is expected to grow at a steady rate of 16.8% owing to Growing Cancer Awareness Programs by Global Health Organizations. For instance, For instance, on 4th February World Cancer Day, World Cancer Day aims to prevent millions of deaths each year by raising awareness about cancer and encouraging governments and individuals around the world to take action against cancer.

Based on type, the market is segmented into kits, instruments, and services. The kits category dominated the market in 2022. The Kits segment in the next-generation sequencing (NGS) based liquid biopsy market plays a crucial role in facilitating the accurate and efficient detection of biomarkers in liquid biopsy samples. Further, the kits are cost-effective and are available at cheaper rates are among the major factors driving the growth of the segment.

On the basis of end-users, the market is categorized into diagnostic laboratories, hospitals, clinics, and others. Among these, the hospital's category held a dominating share of the market in 2022. This is mainly due to the rising number of cancer cases, along with the increasing hospitalization are the major factors responsible for the segmental growth of the hospitals.

For a better understanding of the market adoption of the NGS-based liquid biopsy industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North American region held the largest dominating market share in 2022 with a share of 42.2% in the global NGS-based liquid biopsy market. The market for NGS-based liquid biopsy is witnessing growth in the region due to the presence of developed countries such as the U.S. and Canada in the region. Further, the continuously rising cancer incidences are the major problem faced by the region owing to which the demand for cancer diagnostics increases including NGS-based liquid biopsies. For instance, as per the Globocan 2020 report, 2.5 million cancer cases were reported in 2020 in North America. Among them, 699,274 deaths were reported in the same year.

Some of the major players operating in the market include: GENOMILL HEALTH OY; Avida Biomed; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; F. Hoffmann-La Roche Ltd; Illumina, Inc; QIAGEN; Biocept Inc.; Guardant Health, Inc.; and Lucence Health Inc.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the NGS BASED LIQUID BIOPSY Market
2.2. Research Methodology of the NGS BASED LIQUID BIOPSY Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NGS BASED LIQUID BIOPSY MARKET

6 NGS BASED LIQUID BIOPSY MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY TYPE

7.1. Kits
7.2. Instruments
7.3. Services

8 MARKET INSIGHTS BY END-USER

8.1. Diagnostic Laboratories
8.2. Hospitals
8.3. Clinics
8.4. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World